With Shire takeover bid, AbbVie looks to succeed where Pfizer failed

Carly Helfand

may be working with some of the same advisers who worked on 's so-far- play for AstraZeneca. But after three rejections from target –the latest totaling about $ 46.5 billion–it's not about to make Pfizer's same mistakes.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS